Germline variants and advanced colorectal adenomas

Adenoma prevention with celecoxib trial genome-wide association study

Jiping Wang, Luis Carvajal-Carmona, Jen Hwa Chu, Ann G. Zauber, Michikai Kubo, Koichi Matsuda, Malcolm Dunlop, Richard S. Houlston, Oliver Sieber, Lara Lipton, Peter Gibbs, Nicholas G. Martin, Grant W. Montgomery, Joanne Young, Paul N. Baird, Mark J. Ratain, Yusuke Nakamura, Scott T. Weiss, Ian Tomlinson, Monica M. Bertagnolli

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Identification of single-nucleotide polymorphisms (SNP) associated with development of advanced colorectal adenomas. Experimental Design: Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence. Genome-wide significance was defined as false discovery rate less than 0.05, unadjusted P = 7.4 × 10-7. Validation phase: results were further evaluated using 4,175 familial colorectal adenoma cases and 5,036 controls from patients of European ancestry [COloRectal Gene Identification consortium (CORGI), Scotland, Australia, and VQ58]. Results: Our study identified eight SNPs-associated with advanced-adenoma risk in the APC trial(rs2837156, rs7278863, rs2837237, rs2837241, rs2837254, rs741864 at 21q22.2, and rs1381392 and rs17651822 at 3p24.1, at P < 10 -7 level with OR > 2). Five variants in strong pairwise linkage disequilibrium (rs7278863, rs2837237, rs741864, rs741864, and rs2837241; r 2= 0.8-1) are in or near the coding region for the tight junction adhesion protein, IGSF5. An additional variant associated with advanced adenomas, rs1535989 [minor allele frequency, 0.11; OR, 2.09;95% confidence interval (CI), 1.50-2.91], also predicted colorectal cancer development in a validation analysis (P = 0.019) using a series of adenoma cases or colorectal cancer (CORGI study) and 3 sets of colorectal cancer cases and controls (Scotland, VQ58, and Australia;N = 9,211). Conclusions: Our results suggest that common polymorphisms contribute to the risk of developing advanced adenomas and might also contribute to the risk of developing colorectal cancer. The variant at rs1535989 may identify patients whose risk for neoplasia warrants increased colonoscopic surveillance. Clin

Original languageEnglish (US)
Pages (from-to)6430-6437
Number of pages8
JournalClinical Cancer Research
Volume19
Issue number23
DOIs
StatePublished - Dec 1 2013

Fingerprint

Celecoxib
Genome-Wide Association Study
Adenoma
Colorectal Neoplasms
Scotland
Single Nucleotide Polymorphism
Tight Junction Proteins
Neoplasm Genes
Linkage Disequilibrium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Germline variants and advanced colorectal adenomas : Adenoma prevention with celecoxib trial genome-wide association study. / Wang, Jiping; Carvajal-Carmona, Luis; Chu, Jen Hwa; Zauber, Ann G.; Kubo, Michikai; Matsuda, Koichi; Dunlop, Malcolm; Houlston, Richard S.; Sieber, Oliver; Lipton, Lara; Gibbs, Peter; Martin, Nicholas G.; Montgomery, Grant W.; Young, Joanne; Baird, Paul N.; Ratain, Mark J.; Nakamura, Yusuke; Weiss, Scott T.; Tomlinson, Ian; Bertagnolli, Monica M.

In: Clinical Cancer Research, Vol. 19, No. 23, 01.12.2013, p. 6430-6437.

Research output: Contribution to journalArticle

Wang, J, Carvajal-Carmona, L, Chu, JH, Zauber, AG, Kubo, M, Matsuda, K, Dunlop, M, Houlston, RS, Sieber, O, Lipton, L, Gibbs, P, Martin, NG, Montgomery, GW, Young, J, Baird, PN, Ratain, MJ, Nakamura, Y, Weiss, ST, Tomlinson, I & Bertagnolli, MM 2013, 'Germline variants and advanced colorectal adenomas: Adenoma prevention with celecoxib trial genome-wide association study', Clinical Cancer Research, vol. 19, no. 23, pp. 6430-6437. https://doi.org/10.1158/1078-0432.CCR-13-0550
Wang, Jiping ; Carvajal-Carmona, Luis ; Chu, Jen Hwa ; Zauber, Ann G. ; Kubo, Michikai ; Matsuda, Koichi ; Dunlop, Malcolm ; Houlston, Richard S. ; Sieber, Oliver ; Lipton, Lara ; Gibbs, Peter ; Martin, Nicholas G. ; Montgomery, Grant W. ; Young, Joanne ; Baird, Paul N. ; Ratain, Mark J. ; Nakamura, Yusuke ; Weiss, Scott T. ; Tomlinson, Ian ; Bertagnolli, Monica M. / Germline variants and advanced colorectal adenomas : Adenoma prevention with celecoxib trial genome-wide association study. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 23. pp. 6430-6437.
@article{b1a067716ee34b54b6323b0c0169ff09,
title = "Germline variants and advanced colorectal adenomas: Adenoma prevention with celecoxib trial genome-wide association study",
abstract = "Purpose: Identification of single-nucleotide polymorphisms (SNP) associated with development of advanced colorectal adenomas. Experimental Design: Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence. Genome-wide significance was defined as false discovery rate less than 0.05, unadjusted P = 7.4 × 10-7. Validation phase: results were further evaluated using 4,175 familial colorectal adenoma cases and 5,036 controls from patients of European ancestry [COloRectal Gene Identification consortium (CORGI), Scotland, Australia, and VQ58]. Results: Our study identified eight SNPs-associated with advanced-adenoma risk in the APC trial(rs2837156, rs7278863, rs2837237, rs2837241, rs2837254, rs741864 at 21q22.2, and rs1381392 and rs17651822 at 3p24.1, at P < 10 -7 level with OR > 2). Five variants in strong pairwise linkage disequilibrium (rs7278863, rs2837237, rs741864, rs741864, and rs2837241; r 2= 0.8-1) are in or near the coding region for the tight junction adhesion protein, IGSF5. An additional variant associated with advanced adenomas, rs1535989 [minor allele frequency, 0.11; OR, 2.09;95{\%} confidence interval (CI), 1.50-2.91], also predicted colorectal cancer development in a validation analysis (P = 0.019) using a series of adenoma cases or colorectal cancer (CORGI study) and 3 sets of colorectal cancer cases and controls (Scotland, VQ58, and Australia;N = 9,211). Conclusions: Our results suggest that common polymorphisms contribute to the risk of developing advanced adenomas and might also contribute to the risk of developing colorectal cancer. The variant at rs1535989 may identify patients whose risk for neoplasia warrants increased colonoscopic surveillance. Clin",
author = "Jiping Wang and Luis Carvajal-Carmona and Chu, {Jen Hwa} and Zauber, {Ann G.} and Michikai Kubo and Koichi Matsuda and Malcolm Dunlop and Houlston, {Richard S.} and Oliver Sieber and Lara Lipton and Peter Gibbs and Martin, {Nicholas G.} and Montgomery, {Grant W.} and Joanne Young and Baird, {Paul N.} and Ratain, {Mark J.} and Yusuke Nakamura and Weiss, {Scott T.} and Ian Tomlinson and Bertagnolli, {Monica M.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-13-0550",
language = "English (US)",
volume = "19",
pages = "6430--6437",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Germline variants and advanced colorectal adenomas

T2 - Adenoma prevention with celecoxib trial genome-wide association study

AU - Wang, Jiping

AU - Carvajal-Carmona, Luis

AU - Chu, Jen Hwa

AU - Zauber, Ann G.

AU - Kubo, Michikai

AU - Matsuda, Koichi

AU - Dunlop, Malcolm

AU - Houlston, Richard S.

AU - Sieber, Oliver

AU - Lipton, Lara

AU - Gibbs, Peter

AU - Martin, Nicholas G.

AU - Montgomery, Grant W.

AU - Young, Joanne

AU - Baird, Paul N.

AU - Ratain, Mark J.

AU - Nakamura, Yusuke

AU - Weiss, Scott T.

AU - Tomlinson, Ian

AU - Bertagnolli, Monica M.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Purpose: Identification of single-nucleotide polymorphisms (SNP) associated with development of advanced colorectal adenomas. Experimental Design: Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence. Genome-wide significance was defined as false discovery rate less than 0.05, unadjusted P = 7.4 × 10-7. Validation phase: results were further evaluated using 4,175 familial colorectal adenoma cases and 5,036 controls from patients of European ancestry [COloRectal Gene Identification consortium (CORGI), Scotland, Australia, and VQ58]. Results: Our study identified eight SNPs-associated with advanced-adenoma risk in the APC trial(rs2837156, rs7278863, rs2837237, rs2837241, rs2837254, rs741864 at 21q22.2, and rs1381392 and rs17651822 at 3p24.1, at P < 10 -7 level with OR > 2). Five variants in strong pairwise linkage disequilibrium (rs7278863, rs2837237, rs741864, rs741864, and rs2837241; r 2= 0.8-1) are in or near the coding region for the tight junction adhesion protein, IGSF5. An additional variant associated with advanced adenomas, rs1535989 [minor allele frequency, 0.11; OR, 2.09;95% confidence interval (CI), 1.50-2.91], also predicted colorectal cancer development in a validation analysis (P = 0.019) using a series of adenoma cases or colorectal cancer (CORGI study) and 3 sets of colorectal cancer cases and controls (Scotland, VQ58, and Australia;N = 9,211). Conclusions: Our results suggest that common polymorphisms contribute to the risk of developing advanced adenomas and might also contribute to the risk of developing colorectal cancer. The variant at rs1535989 may identify patients whose risk for neoplasia warrants increased colonoscopic surveillance. Clin

AB - Purpose: Identification of single-nucleotide polymorphisms (SNP) associated with development of advanced colorectal adenomas. Experimental Design: Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence. Genome-wide significance was defined as false discovery rate less than 0.05, unadjusted P = 7.4 × 10-7. Validation phase: results were further evaluated using 4,175 familial colorectal adenoma cases and 5,036 controls from patients of European ancestry [COloRectal Gene Identification consortium (CORGI), Scotland, Australia, and VQ58]. Results: Our study identified eight SNPs-associated with advanced-adenoma risk in the APC trial(rs2837156, rs7278863, rs2837237, rs2837241, rs2837254, rs741864 at 21q22.2, and rs1381392 and rs17651822 at 3p24.1, at P < 10 -7 level with OR > 2). Five variants in strong pairwise linkage disequilibrium (rs7278863, rs2837237, rs741864, rs741864, and rs2837241; r 2= 0.8-1) are in or near the coding region for the tight junction adhesion protein, IGSF5. An additional variant associated with advanced adenomas, rs1535989 [minor allele frequency, 0.11; OR, 2.09;95% confidence interval (CI), 1.50-2.91], also predicted colorectal cancer development in a validation analysis (P = 0.019) using a series of adenoma cases or colorectal cancer (CORGI study) and 3 sets of colorectal cancer cases and controls (Scotland, VQ58, and Australia;N = 9,211). Conclusions: Our results suggest that common polymorphisms contribute to the risk of developing advanced adenomas and might also contribute to the risk of developing colorectal cancer. The variant at rs1535989 may identify patients whose risk for neoplasia warrants increased colonoscopic surveillance. Clin

UR - http://www.scopus.com/inward/record.url?scp=84890303298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890303298&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-0550

DO - 10.1158/1078-0432.CCR-13-0550

M3 - Article

VL - 19

SP - 6430

EP - 6437

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -